“Hims vs Roman” is one of the most common men’s telehealth searches, and it reflects a real point of confusion: many people don’t realize Roman is the men’s vertical of Ro, which makes the comparison fundamentally a Hims vs Ro question. This hims vs roman guide clarifies the relationship between the brands, breaks down pricing across hair loss, ED, weight loss, and mental health, and explains where each platform genuinely differs. The short answer: Roman = Ro’s men’s brand, so comparing Hims and Roman means comparing two competing direct-to-consumer telehealth companies that serve overlapping needs with similar pricing and slightly different positioning. This article is general information, not medical advice — any treatment decision belongs with a licensed clinician who reviews your history.
The relationship — Roman is part of Ro
The company now known as Ro was founded in 2017 as Roman, originally focused on men’s health (specifically erectile dysfunction). It rebranded the parent organization to Ro around 2019-2020 and now operates several verticals: Roman for men’s health, Rory for women’s health (largely deprecated), Zero for smoking cessation, plus body/weight and other unbranded health programs. The Roman name persists in the men’s vertical’s marketing, but the corporate structure, pharmacy, and clinical infrastructure are Ro’s.
This means searching “Hims vs Roman” gets you a comparison of two competing companies — Hims & Hers Health Inc. (parent of Hims and Hers) versus Ro (parent of Roman, Ro’s hair and skin programs, and more). Functionally, this is the same comparison as Hims vs Ro. For broader detail, see our Ro vs Hims head-to-head and our individual Ro review and Hims review. Because both are private companies’ consumer offerings, program names, pricing, and availability shift frequently — treat every figure below as an estimate to verify on each site.
Hims vs Roman pricing across categories
Prices below are approximate and change often with promotions and program updates; confirm the current numbers on each platform before committing.
Hair loss: Both platforms offer generic finasteride at roughly $20-25/month and topical minoxidil at roughly $15-20/month, with combined bundles commonly in the $40-50/month range. At the medication level, the two are essentially identical.
Erectile dysfunction: Generic sildenafil can start around a few dollars per dose at both; generic tadalafil is similar. ED chewable or “hard mint” style bundles typically run somewhere in the $40-60/month range at both. ED is where Roman built its early reputation, so its educational content is slightly more developed, but the underlying treatment options and pricing are broadly equivalent.
Weight loss: Both platforms run a weight-loss program with an intake/visit fee plus an ongoing monthly membership, historically in the ballpark of $80-100 to start and roughly $99-199/month ongoing depending on medication and promotions. Both deliver branded GLP-1 medications; compounded options have largely wound down (see below). Hims has historically run more aggressive promotional pricing. The medication itself dominates total cost.
Mental health: Hims offers anxiety and depression treatment with SSRIs through a clinician, commonly with a modest initial-visit fee plus monthly medication cost. Roman does not currently run a dedicated mental health vertical, so for mental health, Hims is the only choice between these two. If you are in crisis, call or text 988 (the Suicide & Crisis Lifeline) or go to the nearest emergency department rather than using a subscription telehealth service.
Hair loss — Hims vs Roman
Both platforms prescribe the same finasteride 1mg and topical minoxidil 5% with similar supplemental products in their bundles. The clinical outcomes are equivalent because the medications are equivalent, and pricing is essentially the same at the bundle level. Note that finasteride carries a boxed warning history in the broader labeling conversation and can have sexual and mood-related side effects for some men; the decision to start or stop it should be made with the prescribing clinician, not on price alone.
The cleaner option for pure hair-loss focus is Keeps, which doesn’t try to upsell other men’s health products. For Hims vs Roman specifically, the difference for hair loss comes down to which platform’s UX you prefer and any promotional pricing at signup. See our Hims vs Keeps and Keeps vs Roman comparisons.
ED treatment — Hims vs Roman
ED is Roman’s original category. The intake forms, educational content, and overall product depth are slightly more refined at Roman because the platform was built around ED treatment first and expanded outward. Hims’s ED offering is comparable but feels more like one product among many rather than the platform’s centerpiece.
The medications are the same — generic sildenafil, generic tadalafil, and the various chewable formulations. Pricing is essentially equivalent. Because ED can be an early sign of cardiovascular disease and because these drugs interact dangerously with nitrates, the prescribing clinician’s review matters; the platform is a delivery channel, not a substitute for evaluating the underlying cause. Patients wanting in-depth ED-focused content might slightly prefer Roman; patients comparing on price and convenience will find the two largely interchangeable.
Weight loss — Hims vs Roman/Ro
Weight loss is the highest-stakes category for these comparisons because total spend is substantial — patients on GLP-1 medications can spend a few hundred to well over a thousand dollars monthly depending on the medication, insurance, and platform. The difference between Hims and Roman/Ro on the visit fee and membership is small relative to medication cost.
The compounding landscape changed materially in 2025. After the FDA determined that the semaglutide and tirzepatide shortages were resolved (tirzepatide in late 2024, semaglutide in early 2025), the legal basis for large-scale compounding of those molecules wound down over the following months. Most compounded semaglutide and tirzepatide options were phased out, pushing both platforms toward branded products such as Wegovy, Ozempic, Zepbound, and Mounjaro, whose prices are set by their manufacturers. Hims & Hers briefly partnered with Novo Nordisk in 2025 to offer branded Wegovy, but Novo publicly ended that collaboration later in 2025 amid a dispute over marketing and compounding; related telehealth GLP-1 litigation and settlements were reported into early 2026. Because these arrangements are in flux, verify current medication access and pricing directly with each platform before enrolling. See our Ro vs Hims weight loss and Wegovy through Hims vs Ro comparisons for category-specific detail.
GLP-1 medications are prescription drugs with meaningful contraindications (including a personal or family history of medullary thyroid carcinoma or MEN 2) and side effects. Whether one is appropriate — and which one — is a clinical decision made by the prescriber after reviewing your history, not something to choose from a menu based on price.
The “Roman” brand vs the “Ro” rebranding
Some patients use “Roman” and “Ro” interchangeably; others perceive them as different products. The reality is that they are the same company with different naming for different verticals. Searching for “Roman” online typically routes to Ro’s men’s health pages; searching for “Ro” routes to the broader corporate site with all verticals.
This branding can cause confusion in the marketplace — patients sometimes Google “Roman ED treatment” and “Ro hair loss” without realizing they are considering the same parent platform. For comparison purposes, treating Roman as a vertical of Ro and comparing it to Hims as a separate company is the accurate framing.
Customer service and complaints — comparable
Both platforms have documented customer-service complaints around auto-renewal billing, cancellation difficulty, and slow support responses. The complaint patterns are similar at both. Neither is a standout for customer service, and neither is clearly worse than the other. Practical tip: set calendar reminders before quarterly shipments at either platform, and confirm that any cancellation has actually been processed rather than assuming it went through.
How prescribing actually works on these platforms
On both Hims and Roman/Ro, you complete an online intake, and a licensed clinician (physician, nurse practitioner, or physician assistant) reviews it before any prescription is issued. You do not choose your own medication or dose; the clinician does, based on your history, and can decline to prescribe if something isn’t appropriate or safe. Controlled substances and certain higher-risk medications may require additional steps, video visits, or lab work. If a platform ever lets you “pick” a prescription drug with no clinical review, treat that as a red flag. For anything clinical — side effects, dose changes, interactions, or whether a treatment is right for you — talk to the prescribing clinician.
Frequently Asked Questions
Is Roman owned by Ro?
Yes. Roman is the men’s health brand of Ro. The company was founded as Roman in 2017 and rebranded the parent to Ro around 2019-2020. The Roman name persists for the men’s vertical.
Is Hims the same as Hers?
Hims and Hers are separate brands under the same parent company, Hims & Hers Health Inc. Hims serves men’s health; Hers serves women’s health. Both share infrastructure but operate as distinct brands.
Which is cheaper, Hims or Roman?
The two platforms are nearly identical in pricing for hair loss, ED, and most categories. Hims has historically run more aggressive promotional pricing on weight loss. The cost difference is generally small, and promotions change often, so compare current signup pricing for your specific need.
Can I use both Hims and Roman?
Yes. Some patients use Hims for one category (for example, mental health) and Roman/Ro for another (hair loss or ED). There is no exclusivity, though most people prefer to consolidate on one platform for convenience.
Do these platforms still offer compounded semaglutide?
Access to compounded semaglutide and tirzepatide narrowed sharply in 2025 after the FDA declared those shortages resolved and the compounding wind-down took effect. Both platforms now emphasize branded GLP-1 medications, whose prices are set by manufacturers. Because access and rules keep changing, verify what is currently available directly on each platform.
Which has better customer service?
Both have similar complaint volumes proportional to their subscriber bases. Neither stands out. Specific experiences vary by individual interaction rather than reflecting a systematic platform difference.
The bottom line on Hims vs Roman
The comparison is essentially Hims vs Ro, with Roman serving as Ro’s men’s brand. The two are direct competitors with similar pricing across hair loss, ED, and most categories. Hims tends to run more aggressive promotional pricing on weight loss; Roman/Ro has slightly more refined ED-focused content; and mental health is only available through Hims between the two. Customer-service issues affect both similarly. For most patients, the right choice depends on which platform’s promotional pricing fits your specific need at signup, since the underlying clinical models and medications are largely interchangeable. Whatever you choose, the prescription decision is the clinician’s — verify current pricing and program terms on each site before you enroll.
Disclaimer: This article is for general informational purposes only and is not medical advice. It does not endorse, and is not affiliated with, Hims & Hers or Ro/Roman. Prescription treatments — including finasteride, ED medications, SSRIs, and GLP-1 drugs — carry risks and are appropriate only when prescribed by a licensed clinician who has reviewed your medical history. Prices, promotions, medication availability, and company partnerships change frequently and vary by person; every figure here is an estimate to verify directly with the platform. For any clinical question or symptom, consult a qualified healthcare professional. In a mental health crisis, call or text 988; in a medical emergency, call 911.
Sources
- Ro (ro.co) — public program, pricing, and company pages
- Hims & Hers (hims.com / forhims.com) — public program and pricing pages; Hims & Hers Health Inc. investor communications
- U.S. Food & Drug Administration — statements on resolution of the semaglutide and tirzepatide shortages (2024-2025) and compounding wind-down
- Novo Nordisk — public statements on ending its Hims collaboration (2025)
- General reporting on 2025-2026 telehealth GLP-1 litigation and settlements (verify current status)